Skip to content
CompoundSci
All peptides
Research vial labelled TB-500, a Healing and tissue peptide studied in preclinical and clinical literature

TB-500

Thymosin β4 fragment

Thymosin beta-4 has a real preclinical file on cell migration, corneal and cardiac repair. TB-500 is the marketed fragment of it.

General profile

Class
Healing and tissue
Evidence
Early or preclinical only
Studied dose range
2–2.5 mg
Frequency in protocols
2× weekly loading, then weekly
Route
Subcutaneous
Half life
~2–3 days
Reconstitution
3 mL bacteriostatic water per 5 mg vial
Storage
Refrigerated, ~60 days

Timing and cycling in the literature

Usually dosed in the evening window

Twice weekly during a loading phase, then weekly

Multi-day half-life means clock time barely matters. Consistency of the weekly day matters more than the hour.

Reported cycle: 6 weeks on, 4 weeks off

Protocols use a loading phase of four to six weeks then a maintenance or washout phase. The multi-day half-life means tissue levels keep climbing well after the last dose.

Watch for: Head rush or lethargy in the first week, and the same angiogenesis caution as BPC-157.

What it conflicts with

Three separate questions, kept separate. A hard stop means the mechanisms must not run together at all and timing does not fix it. A syringe rule means the same day is fine but one barrel is not. Redundancy is not dangerous, it is paying twice to hit one target.

  • Hard stopBody level hard stop

    TB-500 + The window right after cardiac surgery

    Not alongside an active cardiac recovery regimen

    Bleeding risk and the cardiac drug regimen come first. Pro-angiogenic and vasodilatory compounds can clash with that care. Physician territory, not a timing problem.

  • Hard stopBody level hard stop

    TB-500 + Active cancer, pregnancy or heavy immunosuppression

    Absolute stop with an active cancer history

    Angiogenesis is the whole mechanism people are chasing here, and it acts everywhere in the body, not only in the tendon you care about. Active cancer, pregnancy, major cardiac care and heavy immunosuppression override every stack preference.

  • Hard stopTiming

    TB-500 + Wolverine (BPC-157 + TB-500)

    Duplicate ingredient

    TB-500 is already in the blend and has a multi-day half-life, so an additional standalone dose accumulates fast.

  • Separate syringesSame day fine, same syringe not

    TB-500 + Melanotan II

    Keep Melanotan II alone in the barrel

    Same rule: own draw, and introduce it at least a week apart from any other new compound so a reaction is readable.

  • Separate syringesSame day fine, same syringe not

    TB-500 + BPC-157

    Valid protocol pair, separate syringes by default

    Complementary jobs, local repair signalling versus cell motility and systemic repair logistics. Co-draw stability data is thin, so the default is two syringes on the same day.

  • Pick oneRedundant, pick one

    TB-500 + Wolverine (BPC-157 + TB-500)

    Same target hit twice

    Wolverine is BPC-157 plus TB-500. Running both doubles one half of the pair.

  • Pick oneTiming

    TB-500 + BPC-157

    Commonly paired in the literature

    These two are studied together in repair models with no reported interaction. Still give them separate injection sites so any local reaction is traceable to one compound.

Most syringe compatibility claims here are practice and expert consensus, not peer reviewed mixing studies. A clear liquid after mixing does not prove the compounds are still active, and cloudiness, particles or gelling means discard. Active cancer, pregnancy, major cardiac care and heavy immunosuppression override every stack preference on this page.

See how TB-500 fits your week

The injection scheduler spaces doses using the clinical timing data, flags the pairs above before you draw them, and tells you why.

Model this in the injection scheduler

The studies

Human trials: Early-phase Tβ4 trials exist in dry eye and pressure ulcers. TB-500 itself has none.

Open questions: The fragment is treated as interchangeable with full Tβ4 in marketing, which the data does not establish.

Published papers

Indexed from Europe PMC and refreshed weekly. Each link opens the paper itself.

Search the full literature